



HARVARD
MEDICAL SCHOOL

Cardiovascular Medicine 2015

Updates for the Practitioner

MAY 3-7
BOSTON, MA

New Findings and Advances for:

Atherosclerosis, CAD, and inflammation
Antithrombotic and antiplatelet agents
Heart failure
Devices and procedures in the cardiac cath lab
Electrophysiology interventions
Preventive cardiology
Vascular medicine
Stroke prevention

- > Diagnosis and treatment of acute coronary syndromes
- > Case-based approaches to disease management
- > Emerging technologies in cardiac care
- > Strategies to prevent hospital readmission
- > Aging and end-of-life care

Under the direction of
Samuel Z. Goldhaber, MD
Peter Libby, MD
Patrick T. O'Gara, MD

*This program is among the
highest-rated Harvard Medical
School CME courses.*

Earn up to 42.00 AMA PRA Category 1 Credits™

Register at Cardiovascular.HMSCME.com



HARVARD MEDICAL SCHOOL

Dear Colleague:

On behalf of Brigham and Women's Hospital and Harvard Medical School, for the first time in two years, I invite you to attend our special clinical conference: Cardiovascular Medicine 2015: Updates for Practitioners.

Cardiologists, internists, vascular specialists, hematologists, family practitioners, pharmacists, PAs, and NPs can rely on this program for critical updates and practical education. Past participants will be the first to say that they put this new information to immediate and practical use. This prompt applicability ensures your patients will receive the highest, most up-to-date quality of care and achieve the best possible outcomes. Our curriculum focuses on:

- Acute coronary syndromes
- Advanced heart failure
- Atherosclerosis and inflammation
- Atrial fibrillation
- Cardiomyopathy
- Congenital heart disease
- Pulmonary embolism and pulmonary hypertension
- Thrombosis
- Valvular heart disease
- Vascular medicine

View the complete agenda in this brochure. You'll see that our faculty members, who have won multiple teaching awards, have worked hard to develop a program well suited for cardiovascular medicine specialists as well as generalists and specialists in other fields who care for patients with cardiovascular conditions.

The curriculum also focuses on timely issues and recent advances in areas such as:

- Stroke prevention
- Newly available devices and procedures in the cardiac cath lab and electrophysiology lab
- Preventive cardiology
- Antithrombotics and antiplatelet agents

With so many rapid advances in cardiovascular medicine, it is critically important to ensure your knowledge is complete and up to date. Our program offers new and returning attendees the opportunity to do this.

Offered only once every two years, this course often sells out, so we encourage you to review the complete agenda in this brochure and register as early as possible.

I look forward to seeing and engaging with you.

Best regards.

Sincerely yours,



Samuel Z. Goldhaber, MD

Course Director

Professor of Medicine, Harvard Medical School

Director, Thrombosis Research Group

Senior Staff Cardiologist, Brigham and Women's Hospital

REASONS TO ATTEND

- New guidelines and practice recommendations for lipid therapy
- New findings from megatrials of anti-inflammatory drugs to prevent heart attack and stroke
- Recommendations for avoiding bleeding from "triple therapy"
- Recent advances in patent foramen ovale management
- Best practices for managing advanced heart failure: artificial heart, "bridge to cure," stem cell therapy
- Comprehensive transcatheter aortic valve replacement and mitral valve disease management
- Improving outcomes for patients with stroke prevention in atrial fibrillation using scoring systems, biomarkers, and genetics
- Drug dosing for patients with chronic thromboembolic pulmonary hypertension
- New therapeutic approaches to device therapy to occlude the left atrial appendage and prevent stroke
- New techniques to address massive and submassive pulmonary embolism — new devices, new drugs
- Advances in managing "ventricular tachycardia storm"
- Incorporation of ECMO, ventricular assist devices, and cooling into cardiac resuscitation protocols

Register at Cardiovascular.HMSCME.com

COURSE OVERVIEW

Learning Objectives

Upon completion of this course, participants will be able to:

- Integrate state-of-the-art cardiovascular advances into practice.
- Develop strategies to counsel cardiovascular patients and their families on end-of-life care.
- Determine appropriate management of venous thromboembolism and atrial fibrillation, including drug therapy and surgical interventions.
- Utilize new drugs and treatments that are available for cardiovascular conditions.
- Apply the most recent guidelines in practice when appropriate.

Who Attends

- Cardiologists
- Internists
- Vascular medicine specialists
- Family medicine practitioners
- Interventional cardiologists
- Geriatricians
- Hematologists
- Nurse practitioners
- Physician assistants
- Electrophysiologists
- Hospitalists
- Pharmacists
- Anesthesiologists
- Pathologists
- Emergency medicine physicians

VENUE

The Fairmont Copley Plaza
138 St. James Avenue
Boston, Massachusetts
+1 617-267-5300



ACCOMMODATIONS and TRAVEL

A limited number of rooms have been reserved at The Fairmont Copley Plaza Hotel until April 10, 2015. Please specify that you are enrolled in this course to receive a reduced room rate. Hotel arrangements can also be made online at Cardiovascular.HMSCME.com.

Please do not purchase non-refundable ticket(s) until you have received an email from our office confirming your paid registration.

INQUIRIES

Call 617-384-8600 Mon-Fri 9am – 5pm EST. Send e-mail to HMS-CME@hms.harvard.edu.

PAYMENT, CONFIRMATION, and REFUND POLICY

Payment via credit card (VISA, MasterCard, or American Express) or check only. Telephone, fax, and cash-payment registrations are not accepted. Upon receipt of your paid registration, an email confirmation from the HMS-DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used to send you critical information, such as your registration confirmation, course evaluation, and certificate of participation.

Refunds, less an administrative fee of \$75, will be issued for all cancellations received two weeks prior to the start of the course. No refund will be issued should cancellation occur less than two weeks prior. "No shows" are subject to the full course fee and no refunds will be issued once the conference has started.

Harvard Medical School Faculty

Elliott M. Antman, MD
Joshua A. Beckman, MD, MS
Deepak L. Bhatt, MD, MPH
Ron Blankstein, MD
Marc P. Bonaca, MD, MPH
Eugene Braunwald, MD
John G. Byrne, MD
Enrico Cagliero, MD
Christopher P. Cannon, MD
Susan Cheng, MD
Mark A. Creager, MD
Kevin J. Croce, MD
Akshay Desai, MD, MPH
Elazer Edelman, MD
Laurence Epstein, MD
Samuel Z. Goldhaber, MD
Karen E. Joynt, MD, MPH
Scott Kinlay, MBBS, PhD
Michael J. Landzberg, MD
Richard T. Lee, MD
Peter Libby, MD
Leonard S. Lilly, MD
Joseph Loscalzo, MD, PhD
Laura Mauri, MD, MS

Jessica L. Mega, MD
Mandeep R. Mehra, MD
David A. Morrow, MD
David J. Moslehi, MD
Jane Newburger, MD
Anju Nohria, MD
Patrick O'Gara, MD
Marc A. Pfeffer, MD, PhD
Gregory Piazza, MD, MS
Jorge Plutzky, MD
Donna Polk, MD, MPH
Susan Redline, MD, MPH
Paul M. Ridker, MD, MPH
Christian T. Ruff, MD, MPH
Marc S. Sabatine, MD, MPH
Arthur Sasahara, MD
Benjamin M. Scirica, MD
Scott D. Solomon, MD
Michael L. Steigner, MD
Lynne W. Stevenson, MD
William G. Stevenson, MD
Garrick C. Stewart, MD
Aaron B. Waxman, MD

Guest Faculty

Gary Balady, MD
Professor of Medicine, Boston University School of Medicine

James Fang, MD
Professor of Medicine, University of Utah

Philip J. Podrid, MD
Professor of Medicine, Boston University School of Medicine

ACCREDITATION

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of **42.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for **AMA PRA Category 1 Credits™** can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the **European Continuous Medical Education Credits (ECMEC®)** granted by the UEMS. One **AMA PRA Category 1 Credit™** is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 42.00 ECMEC® Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

This Live activity, Cardiovascular Medicine 2015: Updates for the Practitioner, with a beginning date of 05/03/2015, has been reviewed and is acceptable for up to 42.00 Prescribed credits by the **American Academy of Family Physicians**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACGME COMPETENCIES

This course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies: patient care, medical knowledge, interpersonal and communication skills, professionalism, and systems-based practice.

DAY 1: Sunday, May 3

6:30 am – 7:45 am	Registration and Breakfast
7:45 am – 8:00 am	Seating
8:00 am – 8:15 am	Welcome, Introductions, Course Objectives Samuel Z. Goldhaber, MD; Peter Libby, MD; Patrick O’Gara, MD

ATHEROSCLEROSIS, INFLAMMATION, THROMBOSIS, AND RISK FACTORS

Session Co-Chairs: Samuel Z. Goldhaber, MD and Patrick O’Gara, MD

8:15 am – 8:50 am	Update on the Pathophysiology of Acute Myocardial Infarction Peter Libby, MD
8:50 am – 9:00 am	Discussion, Q&A
9:00 am – 9:35 am	Targeting and Reducing Inflammation in Atherothrombosis Paul M. Ridker, MD, MPH
9:35 am – 9:45 am	Discussion, Q&A
9:45 am – 10:20 am	Dyslipidemia and Cardiometabolic Syndrome Jorge Plutzky, MD
10:20 am – 10:30 am	Discussion, Q&A
10:30 am – 10:55 am	Coffee Break
10:55 am – 11:30 am	Preventive Cardiology: Consensus and Controversy at the Crossroads Donna Polk, MD, MPH
11:30 am – 11:40 am	Discussion, Q&A

THOMAS W. SMITH, MD MEMORIAL LECTURE

Session Chair: Peter Libby, MD

11:40 am – 12:30 pm	Update on Advanced Heart Failure James Fang, MD
12:30 pm – 12:40 pm	Discussion, Q&A
12:40 pm – 1:55 pm	Lunch

VALVULAR HEART DISEASE SYMPOSIUM

Session Chair: Deepak L. Bhatt, MD, MPH

1:55 pm – 2:30 pm	Mitral Valve Disease: Hemodynamics, Clinical Assessment, and Guidelines Patrick O’Gara, MD
2:30 pm – 2:40 pm	Discussion, Q&A
2:40 pm – 3:15 pm	Transcatheter Aortic Valve Replacement Deepak L. Bhatt, MD, MPH
3:15 pm – 3:25 pm	Discussion, Q&A
3:25 pm – 4:00 pm	Integrating Cardiac Surgery and Invasive Cardiology to Tackle Valvular and Coronary Heart Disease: A Reboot to Optimize Cardiovascular Services John G. Byrne, MD
4:00 pm – 4:10 pm	Discussion, Q&A
4:10 pm – 4:30 pm	Break for Snacks

ELECTROPHYSIOLOGY: STATE OF THE ART

Session Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD

4:30 pm – 5:05 pm	Stroke Prevention in Atrial Fibrillation: Epidemiology and Risk Assessment, Including Scoring Systems, Biomarkers, and Genetics Christian T. Ruff, MD, MPH
5:05 pm – 5:15 pm	Discussion, Q&A
5:15 pm – 5:50 pm	Stroke Prevention in Atrial Fibrillation: Warfarin, Antiplatelet Therapy, and Novel Anticoagulants: Where Do We Stand? Has the Dust Settled? Samuel Z. Goldhaber, MD
5:50 pm – 6:00 pm	Discussion, Q&A
6:00 pm – 6:35 pm	Atrial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD
6:35 pm – 6:45 pm	Discussion, Q&A
6:45 pm – 7:20 pm	“Ventricular Tachycardia Storm” and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD
7:20 pm – 7:30 pm	Discussion, Q&A
7:30 pm	ADJOURN DAY 1

Program changes/substitutions may be made without notice.

Day 2: Monday, May 4

CONGENITAL HEART DISEASE AND PULMONARY HYPERTENSION

Session Chair: Samuel Z. Goldhaber, MD

8:00 am – 8:35 am	Neurocognitive Deficits in Adults with Congenital Heart Disease: Emerging Recognition of a Common and Vexing Problem: Novel Management Strategies Jane Newburger, MD
8:35 am – 8:45 am	Discussion, Q&A
8:45 am – 9:20 am	Patent Foramen Ovale: Stroke and Migraine Risk, and Evidence-Based Trials Supporting Aspirin, Anticoagulation, or Mechanical Closure Michael J. Landzberg, MD
9:20 am – 9:30 am	Discussion, Q&A
9:30 am – 10:05 am	Pulmonary Arterial Hypertension: Classification, Diagnosis, and Emerging Therapies Aaron B. Waxman, MD
10:05 am – 10:15 am	Discussion, Q&A
10:15 am – 10:40 am	Coffee Break

FEATURED PRESENTATION: DEPARTMENT OF MEDICINE CHAIR’S LECTURE

Session Chair: Peter Libby, MD

10:40 am – 11:15 am	Heyde’s Syndrome: Bedside-to-Bench Pathophysiology in Patients with Aortic Stenosis and Gastrointestinal Bleeding Joseph Loscalzo, MD, PhD
11:15 am – 11:25 am	Discussion, Q&A

ADVANCED HEART FAILURE AND CARDIOMYOPATHY — PART 1

Session Chair: Mandeep R. Mehra, MD

11:25 am – 12:00 pm	Advanced Heart Failure: Principal Management Strategies for Inpatients Garrick C. Stewart, MD
12:00 pm – 12:10 pm	Discussion, Q&A
12:10 pm – 12:45 pm	Technological Update on Cardiopulmonary Support Devices: Total Artificial Heart, Extracorporeal Membrane Oxygenation, and Ventricular Assist Devices Mandeep R. Mehra, MD
12:45 pm – 12:55 pm	Discussion, Q&A
12:55 pm – 2:00 pm	Lunch

ADVANCED HEART FAILURE AND CARDIOMYOPATHY — PART 2

Session Chair: Mandeep R. Mehra, MD

2:00 pm – 2:35 pm	Outpatient Strategies for Preventing Hospital Readmission due to Exacerbations of Congestive Heart Failure Akshay Desai, MD, MPH
2:35 pm – 2:45 pm	Discussion, Q&A
2:45 pm – 3:20 pm	Preserved Ejection Fraction Heart Failure: Epidemiology, Pathophysiology, Emerging Innovative Management Strategies Scott D. Solomon, MD
3:20 pm – 3:30 pm	Discussion, Q&A
3:30 pm – 4:05 pm	Cardiac Regeneration and Reversal of Heart Failure Richard T. Lee, MD
4:05 pm – 4:15 pm	Discussion, Q&A
4:15 pm – 4:50 pm	Systemic Arterial Hypertension: Renal Artery Denervation for Resistant Disease Deepak L. Bhatt, MD, MPH
4:50 pm – 5:00 pm	Discussion, Q&A
5:00 pm – 5:15 pm	Transition to Breakout Sessions

BREAKOUT SESSIONS I/II—VASCULAR MEDICINE AND STROKE PREVENTION IN ATRIAL FIBRILLATION

5:15 pm – 6:05 pm	Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD
	Session II: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD
6:05 pm – 6:15 pm	Transition to Breakout Sessions
6:15 pm – 7:05 pm	Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD
	Session II: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD
7:05 pm	ADJOURN DAY 2

Register at Cardiovascular.HMSCME.com

Day 3: Tuesday, May 5

THROMBOEMBOLISM, ANTIPLATELET AGENTS, AND ANTITHROMBOTICS

Session Chair: Arthur Sasahara, MD and Patrick O'Gara, MD

8:00 am – 8:50 am	Management of Pulmonary Embolism and Deep Vein Thrombosis, Including Pathophysiology, Risk Stratification, Novel Oral Anticoagulants, Thrombolytic Therapy, Pharmacomechanical Therapy in the Cath Lab, Surgical Embolectomy, and Options for Extended Duration Anticoagulation Samuel Z. Goldhaber, MD
8:50 am – 9:00 am	Discussion Q&A
9:00 am – 9:35 am	Chronic Venous Insufficiency and Postthrombotic Syndrome of the Legs: Diagnosis, Classification, Pathophysiology, Guidelines for Management, and Endovascular Laser Therapy Gregory Piazza, MD, MS
9:35 am – 9:45 am	Discussion, Q&A
9:45 am – 10:20 am	Heart Failure and Thrombosis: Which Patients Should I Anticoagulate? Marc A. Pfeffer, MD, PhD
10:20 am – 10:30 am	Discussion, Q&A
10:30 am – 10:55 am	Coffee Break

VASCULAR MEDICINE – PART 1

Session Chair: Samuel Z. Goldhaber, MD and Gregory Piazza, MD, MS

10:55 am – 11:30 am	Evaluation and Secondary Stroke Prevention after Transient Ischemic Attack or Nonembolic Ischemic Stroke Mark A. Creager, MD
11:30 am – 11:40 am	Discussion, Q&A
11:40 am – 12:15 pm	Principles of Preoperative Evaluation, Including Risk Prediction, Workup, Prescription of Beta Blockers or Statins, and Management of Postoperative “Troponin Leaks” Joshua A. Beckman, MD, MS
12:15 pm – 12:25 pm	Discussion, Q&A
12:25 pm – 2:00 pm	Lunch

PERICARDITIS MULTIMODALITY CASE DISCUSSION

2:00 pm – 2:10 pm	Case presentation Samuel Z. Goldhaber, MD
2:10 pm – 2:20 pm	Electrocardiogram, Echocardiogram, and Sequential Magnetic Resonance Imaging Ron Blankstein, MD
2:20 pm – 2:40 pm	Idiopathic Pericarditis: Choice of Anti-Inflammatory Agent(s), Duration of Therapy, Role of Colchicine, and Tips on Weaning from Prednisone Leonard S. Lilly, MD
2:40 pm – 2:50 pm	Discussion, Q&A

AGING AND END OF LIFE

Session Chair: Peter Libby, MD

2:50 pm – 3:25 pm	Cardiovascular Medicine in the Elderly: Epidemiology, Pathophysiology, and Special Patient-Based Considerations Susan Cheng, MD
3:25 pm – 3:35 pm	Discussion, Q&A
3:35 pm – 4:10 pm	Guiding Cardiovascular Patients and Their Families at the End of Life Lynne W. Stevenson, MD
4:10 pm – 4:20 pm	Discussion, Q&A
4:20 pm – 4:35 pm	Transition to Breakout Sessions

BREAKOUT SESSIONS III/IV

4:35 pm – 5:25 pm	Session III: Bleeding and Clotting Cases Gregory Piazza, MD, MS
	Session IV: Difficult Dilemmas That My Patients and I Have Confronted Patrick O'Gara, MD
5:25 pm – 5:35 pm	Transition to Breakout Sessions
5:35 pm – 6:25 pm	Session III: Bleeding and Clotting Cases Gregory Piazza, MD, MS
	Session IV: Difficult Dilemmas That My Patients and I Have Confronted Patrick O'Gara, MD
6:25 pm	ADJOURN DAY 3

Day 4: Wednesday, May 6

ACUTE CORONARY SYNDROMES – PART 1

Session Co-Chairs: Marc S. Sabatine, MD, MPH and David A. Morrow, MD

8:00 am – 8:15 am	TIMI Group Overview Marc S. Sabatine, MD, MPH
8:15 am – 8:20 am	Discussion, Q&A
8:20 am – 9:00 am	ST Segment Elevation Myocardial Infarction, Including Mechanical Complications, Guideline Updates, and Novel/Emerging Therapies Elliott M. Antman, MD
9:00 am – 9:40 am	Non-ST Segment Elevation Myocardial Infarction and Unstable Angina: Risk Assessment to Determine Which Patients Should Go to the Cath Lab, the Optimal Timing for Cath, and Guideline Updates Christopher P. Cannon, MD
9:40 am – 10:00 am	Discussion, Q&A for Drs. Antman and Cannon
10:00 am – 10:25 am	Coffee Break
10:25 am – 11:00 am	Acute Coronary Syndrome: Role (if any) for Genetic Profiling and Functional Testing to Select Antiplatelet Therapy, and How to Balance the Possibility of Major Bleeding versus Reduction in Cardiovascular Mortality when Prescribing Long-Term Thrombin Inhibition Therapy to Prevent Recurrent Acute Coronary Syndrome Jessica L. Mega, MD
11:00 am – 11:10 am	Discussion, Q&A

KENNETH L. BAUGHMAN, MD MEMORIAL LECTURE

Session Chair: Patrick O'Gara, MD

11:10 am – 12:00 pm	Exercise and Cardiovascular Disease: Observations, Mechanisms and Clinical Applications Gary Balady, MD
12:00 pm – 12:10 pm	Discussion, Q&A
12:10 pm – 1:20 pm	Lunch

ACUTE CORONARY SYNDROMES – PART 2

Session Co-Chairs: Marc S. Sabatine, MD, MPH and David A. Morrow, MD

1:20 pm – 1:55 pm	Challenges for Cardiac Intensive Care: Cooling Protocols, Ventilator Settings, Extracorporeal Membrane Oxygenation, Resuscitation Science Benjamin M. Scirica, MD
1:55 pm – 2:05 pm	Discussion, Q&A
2:05 pm – 2:40 pm	Cardiac Biomarkers: Which Should We Order, When Should We Order, and How Should We Integrate High-Sensitivity Troponin Assays into Clinical Care? David A. Morrow, MD
2:40 pm – 2:50 pm	Discussion, Q&A
2:50 pm – 3:25 pm	Can Coronary CT Angiography Accelerate our Triage of Patients with Suspected Acute Coronary Syndrome, Shorten Emergency Department Visits, Prevent Overnight Hospitalizations, and Help Us Detect Patients with Vulnerable Plaque? Multiple Rapid-Fire Coronary CT Images Michael L. Steigner, MD
3:25 pm – 3:35 pm	Discussion, Q&A
3:35 pm – 3:50 pm	Transition to Breakout Sessions

BREAKOUT SESSIONS V/VI – CASE-BASED CLINICAL CARDIOLOGY

3:50 pm – 4:40 pm	Session V: Cardiac Intensive Care Unit Cases Benjamin M. Scirica, MD
	Session VI: Cardio-Oncology Cases Anju Nohria, MD
4:40 pm – 4:50 pm	Transition To Breakout Sessions
4:50 pm – 5:40 pm	Session V: Cardiac Intensive Care Unit Cases Benjamin M. Scirica, MD
	Session VI: Cardio-Oncology Cases Anju Nohria, MD
5:40 pm	ADJOURN DAY 4

Day 5: Thursday, May 7

VASCULAR MEDICINE – PART 2

Session Chair: Samuel Z. Goldhaber, MD

8:00 am – 8:35 am	Diseases of the Aorta, Including Screening Guidelines for Abdominal Aortic Aneurysm Patrick O’Gara, MD
8:35 am – 8:45 am	Discussion, Q&A
8:45 am – 9:20 am	“Code Aorta”: How to Organize a Strategic Multidisciplinary Response to a Potentially Fatal Vascular Emergency: Initial Results and Rapid-Fire Case Presentations Marc P. Bonaca, MD, MPH
9:20 am – 9:30 am	Discussion, Q&A
9:30 am – 10:05 am	Percutaneous Interventional Therapies for Vascular Diseases: How to Expand the Services of the Cath Lab Beyond Coronary Intervention Scott Kinlay, MBBS, PhD
10:05 am – 10:15 am	Discussion, Q&A
10:15 am – 10:40 am	Coffee Break

EUGENE BRAUNWALD, MD LECTURE

Session Chair: Peter Libby, MD

10:40 am – 11:30 am	Cardiovascular Medicine: Pivotal Innovations and Dissemination of New Findings Eugene Braunwald, MD
11:30 am – 11:40 am	Discussion, Q&A

CARDIAC CATH LAB

Session Co-Chairs: Laura Mauri, MD, MS and Kevin J. Croce, MD

11:40 am – 12:15 pm	Innovations in Bare Metal, Drug-Eluting, Self-Expanding, and Absorbable Coronary Stents Elazer Edelman, MD
12:15 pm – 12:25 pm	Discussion, Q&A
12:25 pm – 1:10 pm	Lunch
1:10 pm – 1:45 pm	Coronary Stenting: The Dual Antiplatelet Therapy Study (DAPT Study) of Drug-Eluting and Bare Metal Stents: Optimal Duration of Therapy Based Upon Results of a Megatrial Laura Mauri, MD, MS
1:45 pm – 1:55 pm	Discussion, Q&A
1:55 pm – 2:30 pm	Impact of Public Reporting and Outlier Status Identification on Percutaneous Coronary Intervention Case Selection Karen E. Joynt, MD, MPH
2:30 pm – 2:40 pm	Discussion, Q&A
2:40 pm – 3:15 pm	Optical Coherence Tomography, Fractional Flow Reserve, and Emerging Technologies to Inform Decision Making in the Cardiac Cath Lab Kevin J. Croce, MD
3:15 pm – 3:25 pm	Discussion, Q&A

INTERSECTION OF CARDIOVASCULAR AND INTERNAL MEDICINE

Session Chair: Patrick O’Gara, MD

3:25 pm – 4:00 pm	Sleep-Disordered Breathing: Relationship to Heart Failure, Atrial Fibrillation, and Pulmonary Hypertension Susan Redline, MD, MPH
4:00 pm – 4:10 pm	Discussion, Q&A
4:10 pm – 4:45 pm	What Cardiovascular Specialists Need to Know about Diabetes Mellitus Enrico Cagliero, MD
4:45 pm – 4:55 pm	Discussion, Q&A
4:55 pm – 5:00 pm	General Discussion, Wrap-up
5:00 pm	ADJOURN DAY 5



HARVARD
MEDICAL SCHOOL

Registration Information

Cardiovascular Medicine 2015

(Course #352555)

You can register by credit card (VISA, MasterCard or American Express) online at Cardiovascular.HMSCME.com.

	Course Tuition
Physicians	\$1,495
Allied Health Professionals and Physicians in Training	\$1,295
* Course tuition includes a flash drive with the course materials. Printed materials are optionally available at an additional fee of \$50. Check the optional “Printed materials” box above to receive printed materials and add \$50 to the tuition to calculate your full registration fee.	

* All fees shown in USD.

Tuition Payment, Confirmation, and Refund Policy

Refunds, less an administrative fee of \$75, will be issued for all cancellations received two weeks prior to the start of the course. No refund will be issued should cancellation occur less than two weeks prior. “No shows” are subject to the full course fee and no refunds will be issued once the conference has started. Please do not make non-refundable travel arrangements until you have received an email confirming your registration.

DISCLOSURE POLICY: Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g., planners, faculty, reviewers, and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

Register at Cardiovascular.HMSCME.com